You are currently using an unsupported browser which could affect the appearance and functionality of this website. Please consider upgrading to the latest version or using alternatives such as Mozilla Firefox, Google Chrome or Microsoft Edge.

Antenatal corticosteroids to reduce neonatal morbidity and mortality (Green-top Guideline No. 74)

Antenatal corticosteroids to reduce neonatal morbidity and mortality (Green-top Guideline No. 74) The aim of this guideline is to provide evidence-based recommendations on the use of antenatal corticosteroids in women at risk of preterm birth or undergoing caesarean birth at term.

COVID disclaimer: This guideline was developed as part of the regular programme of Green-top Guidelines, as outlined in our document Developing a Green-top Guideline: Guidance for developers (PDF), and prior to the emergence of COVID-19.

Maternal administration of antenatal corticosteroids before anticipated preterm birth is one of the most important interventions to improve neonatal outcomes.

They are effective in reducing neonatal respiratory morbidity and other complications of prematurity.

The aim of this guideline is to provide evidence-based recommendations on the use of antenatal corticosteroids in women at risk of preterm birth or undergoing caesarean birth at term.

This guideline was developed as part of the regular programme of Green-top Guidelines, as outlined in our document Developing a Green-top Guideline: Guidance for developers (PDF), and prior to the emergence of COVID-19.

Please note that the information provided in this update will be considered for update by the RCOG Guidelines Committee 3 years after publication, with an intermediate assessment of the need to update 2 years after publication.


Developers' declarations of interest

Available on request.

 

Additional Guidance content on eLearning

We have developed a hub of bitesize video summaries and infographics to break down the key points from our Green-top Guidelines and Scientific Impact Papers.

This page was last reviewed 17 February 2022.